VIDEO: Results from SEQUENCE trial ‘important’ for treatment selection in Crohn’s
Click Here to Manage Email Alerts
In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, recaps results from the SEQUENCE trial, which were presented at Digestive Disease Week 2024.
The head-to-head trial assessed the safety and efficacy of Skyrizi (risankizumab, AbbVie) and Stelara (ustekinumab, Janssen) among patients with moderate to severe Crohn’s disease, and found that more patients who failed anti-TNF therapy achieved biologic remission with risankizumab.
Although outcomes were similar between the two agents initially, “at 1 year, for the endpoint of superiority, risankizumab was superior,” Mahadevan, who also is a professor of gastroenterology at the university, said.
“Statistically, going back, it was also superior at induction and met all the secondary endpoints, including endoscopic response and healing. That’s going to be important going forward as we make our decisions on therapy.”
Reference:
- Dubinsky MC, et al. Risankizumab vs. ustekinumab for the achievement of clinical remission and reduction in inflammatory biomarkers in patients with moderate to severe Crohn’s disease: Results from the phase 3b SEQUENCE trial. Presented at: Digestive Disease Week; May 18-21, 2024; Washington (hybrid).
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts